Table 1.
Patient and treatment characteristics.
| Total | C-PCI | HA-PCI | p value | ||||
|---|---|---|---|---|---|---|---|
| n = 106 | % | n = 58 | % | n = 48 | % | ||
| Age, years | |||||||
| Median | 65 | 65 | 64 | 0.424 | |||
| (Range) | (37–82) | (53–82) | (37–79) | ||||
| Sex | |||||||
| Male | 93 | 87.7 | 54 | 93.1 | 39 | 81.3 | 0.064 |
| Female | 13 | 12.3 | 4 | 6.9 | 9 | 18.8 | |
| ECOG PS | |||||||
| 0, 1 | 101 | 95.3 | 55 | 94.8 | 45 | 93.8 | 0.842 |
| 2 | 5 | 4.7 | 3 | 5.2 | 2 | 4.2 | |
| T stage | |||||||
| T1 | 17 | 16.0 | 7 | 12.1 | 10 | 20.8 | 0.127 |
| T2 | 33 | 31.1 | 21 | 36.2 | 12 | 25.0 | |
| T3 | 25 | 23.6 | 10 | 17.2 | 15 | 31.3 | |
| T4 | 31 | 29.2 | 20 | 34.5 | 11 | 22.9 | |
| N stage | |||||||
| N0 | 12 | 11.3 | 8 | 13.8 | 4 | 8.3 | 0.741 |
| N1 | 13 | 12.3 | 8 | 13.8 | 5 | 10.4 | |
| N2 | 57 | 53.8 | 30 | 51.7 | 27 | 56.3 | |
| N3 | 24 | 22.6 | 12 | 20.7 | 12 | 25.0 | |
| AJCC stage (7th edition) | |||||||
| I | 7 | 6.6 | 5 | 8.6 | 2 | 4.2 | 0.796 |
| II | 11 | 10.4 | 6 | 10.3 | 5 | 10.4 | |
| IIIA | 43 | 40.6 | 22 | 37.9 | 21 | 43.8 | |
| IIIB | 45 | 42.5 | 25 | 43.1 | 20 | 41.7 | |
| Initial treatment | |||||||
| RT alone | 1 | 0.9 | 0 | 0.0 | 1 | 2.1 | 0.063 |
| Concurrent CRT | 98 | 92.5 | 51 | 87.9 | 47 | 97.9 | |
| Sequential CRT | 4 | 3.8 | 4 | 6.9 | 0 | 0.0 | |
| Surgery | 3 | 2.8 | 3 | 5.2 | 0 | 0.0 | |
| Chemotherapy regimen | |||||||
| None | 1 | 0.9 | 0 | 0.0 | 1 | 2.1 | 0.114 |
| EP | 102 | 96.2 | 55 | 94.8 | 47 | 97.9 | |
| Others | 3 | 2.8 | 3 | 5.2 | 0 | 0.0 | |
| Chemotherapy cycles | |||||||
| 4 | 69 | 65.1 | 43 | 74.1 | 26 | 54.2 | 0.043 |
| 6 | 36 | 34.0 | 15 | 25.9 | 21 | 43.8 | |
| Thoracic RT dose (Gy) | |||||||
| Median | 54 | 54 | 63 | < 0.001 | |||
| (Range) | (30.6–70.2) | (37.-64.5) | (30.6–72) | ||||
| Thoracic RT fraction size (Gy) | |||||||
| Median | 2 | 2 | 2.1 | 0.097 | |||
| (Range) | (1.5–15) | (1.8–15) | (1.5–2.5) | ||||
| Thoracic RT fractions | |||||||
| Median | 30 | 28 | 30 | 0.036 | |||
| (Range) | (3–35) | (3–33) | (17–35) | ||||
| Thoracic RT total dose (EQD2) | |||||||
| < 60 Gy | 38 | 84.4 | 5 | 11.1 | 43 | 47.8 | < 0.001 |
| ≥ 60 Gy | 7 | 15.6 | 40 | 88.9 | 47 | 52.2 | |
| Thoracic RT modality | |||||||
| 3D CRT | 52 | 50.5 | 49 | 89.1 | 3 | 6.3 | < 0.001 |
| IMRT | 51 | 49.5 | 6 | 10.9 | 45 | 93.8 | |
| Initial treatment response | |||||||
| CR | 9 | 8.5 | 8 | 13.8 | 1 | 2.1 | 0.023 |
| PR | 94 | 88.7 | 47 | 81.0 | 47 | 97.9 | |
| SD | 3 | 2.8 | 3 | 5.2 | 0 | 0.0 | |
| PCI modality | |||||||
| 3D CRT | 57 | 53.8 | 56 | 96.6 | 0 | 0.0 | < 0.001 |
| IMRT | 49 | 46.2 | 2 | 3.4 | 48 | 100.0 | |
| Interval, initial treatment to PCI (days) | |||||||
| Median | 112 | 125 | 105 | 0.003 | |||
| (Range) | (68–312) | (69–312) | (68–167) | ||||
| Interval, last treatment to PCI (days) | |||||||
| Median | 28 | 28 | 27 | 0.424 | |||
| (Range) | (0–146) | (7–146) | (0–116) | ||||
| Treatment period | |||||||
| Median | 2014 | 2011 | 2017 | < 0.001 | |||
| (Range) | (2007–2018) | (2007–2016) | (2015–2018) | ||||
C-PCI conventional prophylactic cranial irradiation, HA-PCI hippocampus-avoidance PCI, ECOG PS Eastern Cooperative Oncology Group Performance Status, AJCC American Joint Committee on Cancer, RT radiotherapy, CRT chemoradiotherapy, EP etoposide/cisplatin, EQD2 Equivalent dose in 2 Gy fractions, α/β = 10, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, CR complete response, PR partial response, SD stable disease.